2
Clinical Trials associated with Pertuzumab biosimilar (Biocad) / Active, not recruitingPhase 3 A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta? as Neoadjuvant Therapy of HER2-Positive Breast Cancer
The goal of this study is to compare the efficacy and safety of BCD-178 and Perjeta as neoadjuvant therapy for HER2-positive breast cancer.
Subjects with histologically confirmed diagnosis of HER2-positive invasive breast cancer (stage II-III, tumor size > 2 cm), with no estrogen (ER) and progesterone (PR) receptors will be randomized to one of two treatment groups (BCD-178 group or Perjeta group) in a 1:1 ratio.
A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers
This is a double-blind, comparative, randomized phase I study comparing pharmacokinetics, safety and immunogenicity profiles of a biosimilar pertuzumab (BCD-178) and Perjeta after a single intravenous infusion in healthy male volunteers
100 Clinical Results associated with Pertuzumab biosimilar (Biocad)
100 Translational Medicine associated with Pertuzumab biosimilar (Biocad)
100 Patents (Medical) associated with Pertuzumab biosimilar (Biocad)
100 Deals associated with Pertuzumab biosimilar (Biocad)